Trials / Unknown
UnknownNCT02619097
Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of the trial are to assess the safety and pharmacokinetics profile of pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.
Detailed description
The study started from the lowest dose, 0.08mg/kg, each group will enroll 4 to 6 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegol-sihematide injection | single dose |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-12-01
- Completion
- 2016-03-01
- First posted
- 2015-12-02
- Last updated
- 2015-12-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02619097. Inclusion in this directory is not an endorsement.